Holen Sie sich die Stockscreener-App
17.88
0.00%
0.00
Handel nachbörslich:
17.88
Schlusskurs vom Vortag:
$17.88
Offen:
$17.9
24-Stunden-Volumen:
1.26M
Relative Volume:
1.21
Marktkapitalisierung:
$2.05B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-12.77
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
+3.20%
1M Leistung:
+4.93%
6M Leistung:
-40.38%
1J Leistung:
+6.43%
1-Tages-Spanne:
$17.68
$18.30
1-Wochen-Bereich:
$16.96
$18.70
52-Wochen-Spanne:
$14.17
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
17.88 | 2.05B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st
Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India
NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView
Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World
Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus
Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria
NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Yahoo Finance
Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus
Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data By Investing.com - Investing.com South Africa
Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus
Novocure announces results from Phase 3 PANOVA-3 trial - TipRanks
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 - GuruFocus
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Lelezard
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | NVCR Stock News - GuruFocus
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance
NovoCure Ltd (NVCR) Shares Gap Down to $18.5801 on May 30 - GuruFocus
Nuveen Asset Management LLC Lowers Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure Announces Upcoming Investor Events | NVCR Stock News - GuruFocus
Novocure Announces Upcoming Investor Events - Yahoo Finance
Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st
BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Dimensional Fund Advisors LP Sells 3,016 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? - Yahoo Finance
Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Raymond James Financial Inc. Purchases Shares of 11,672 NovoCure Limited (NASDAQ:NVCR) - Defense World
Investor Network: Novocure Ltd. to Host Earnings Call - ACCESS Newswire
NovoCure Limited (NASDAQ:NVCR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 20.62, Down -3.28 - DWinneX
Envestnet Asset Management Inc. Buys New Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
Mariner LLC Acquires Shares of 8,631 NovoCure Limited (NASDAQ:NVCR) - Defense World
Comparing Meihua International Medical Technologies (NASDAQ:MHUA) & NovoCure (NASDAQ:NVCR) - Defense World
Ratio Analysis: Unpacking NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
A year in review: NovoCure Ltd (NVCR)’s performance in the last year - uspostnews.com
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
NovoCure Ltd’s latest rating changes from various analysts - knoxdaily.com
What is NovoCure Ltd (NVCR) Stock Return on Shareholders’ Capital? - Sete News
Russell Investments Group Ltd. Sells 2,135 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure First Quarter 2025 Earnings: Beats Expectations - simplywall.st
H.C. Wainwright maintains Buy on NovoCure, $38 price target By Investing.com - Investing.com Canada
NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novocure Ltd-Aktie (NVCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):